Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low-risk TAVR loses ground at 2 years in PARTNER 3

Key clinical point: Key outcomes were similar in low-surgical-risk transcatheter and surgical aortic valve replacement at 2 years.

Major finding: At 2 years, 11.5% of low-surgical-risk transcatheter aortic valve replacement patients had died, had a stroke, or had been rehospitalized, compared with 17.4% of surgical aortic valve replacement patients.

Study details: The PARTNER 3 trial randomized 1,000 patients at low surgical risk to transcatheter aortic valve replacement or surgical aortic valve replacement for severe aortic valve stenosis.

Disclosures: The presenter reported receiving research funding from Edwards Lifesciences, sponsor of the PARTNER 3 trial.


Mack MJ. ACC 2020, Abstract 405-16.